Literature DB >> 16178856

T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

R Franssila1, J Auramo, S Modrow, M Möbs, C Oker-Blom, P Käpylä, M Söderlund-Venermo, K Hedman.   

Abstract

Human parvovirus B19 is a small non-enveloped DNA virus with an icosahedral capsid consisting of proteins of only two species, the major protein VP2 and the minor protein VP1. VP2 is contained within VP1, which has an additional unique portion (VP1u) of 227 amino acids. We determined the ability of eukaryotically expressed parvovirus B19 virus-like particles consisting of VP1 and VP2 in the ratio recommended for vaccine use, or of VP2 alone, to stimulate, in an HLA class II restricted manner, peripheral blood mononuclear cells (PBMC) to proliferate and to secrete interferon gamma (IFN-gamma) and interleukin (IL)-10 cytokines among recently and remotely B19 infected subjects. PBMC reactivity with VP1u was determined specifically with a prokaryotically expressed VP1u antigen. In general, B19-specific IFN-gamma responses were stronger than IL-10 responses in both recent and remote infection; however, IL-10 responses were readily detectable among both groups, with the exception of patients with relapsed or persisting symptoms who showed strikingly low IL-10 responses. Whereas VP1u-specific IFN-gamma responses were very strong among the recently infected subjects, the VP1u-specific IFN-gamma and IL-10 responses were virtually absent among the remotely infected subjects. The disappearance of VP1u-specific IFN-gamma expression is surprising, as B-cell immunity against VP1u is well maintained.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16178856      PMCID: PMC1809488          DOI: 10.1111/j.1365-2249.2005.02886.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  50 in total

1.  Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy.

Authors:  M Marzi; A Vigano; D Trabattoni; M L Villa; A Salvaggio; E Clerici; M Clerici
Journal:  Clin Exp Immunol       Date:  1996-10       Impact factor: 4.330

Review 2.  Immunological memory and protective immunity: understanding their relation.

Authors:  R Ahmed; D Gray
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

3.  Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties.

Authors:  C Lunardi; M Tiso; L Borgato; L Nanni; R Millo; G De Sandre; A B Severi; A Puccetti
Journal:  Eur J Immunol       Date:  1998-03       Impact factor: 5.532

4.  Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19.

Authors:  M Söderlund; C S Brown; W J Spaan; L Hedman; K Hedman
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

5.  T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.

Authors:  Rauli Franssila; Klaus Hedman
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

6.  Chronic parvovirus infection in a presumably immunologically healthy woman.

Authors:  H Faden; G W Gary; L J Anderson
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

7.  Human parvovirus B19 as a causative agent for rheumatoid arthritis.

Authors:  Y Takahashi; C Murai; S Shibata; Y Munakata; T Ishii; K Ishii; T Saitoh; T Sawai; K Sugamura; T Sasaki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

8.  A nonlethal rat parvovirus infection suppresses rat T lymphocyte effector functions.

Authors:  M D McKisic; F X Paturzo; D J Gaertner; R O Jacoby; A L Smith
Journal:  J Immunol       Date:  1995-10-15       Impact factor: 5.422

9.  Association of symptomatic acute human parvovirus B19 infection with human leukocyte antigen class I and II alleles.

Authors:  Jonathan R Kerr; Derek L Mattey; Wendy Thomson; Kay V Poulton; William E R Ollier
Journal:  J Infect Dis       Date:  2002-07-24       Impact factor: 5.226

10.  Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection.

Authors:  A D Wagner; J J Goronzy; E L Matteson; C M Weyand
Journal:  Mayo Clin Proc       Date:  1995-03       Impact factor: 7.616

View more
  7 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

Review 2.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  Tracking of peptide-specific CD4+ T-cell responses after an acute resolving viral infection: a study of parvovirus B19.

Authors:  Victoria Kasprowicz; Adiba Isa; Thomas Tolfvenstam; Katie Jeffery; Paul Bowness; Paul Klenerman
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

4.  Collapsing glomerulopathy in a young woman with APOL1 risk alleles following acute parvovirus B19 infection: a case report investigation.

Authors:  Whitney Besse; Sherry Mansour; Karan Jatwani; Cynthia C Nast; Ursula C Brewster
Journal:  BMC Nephrol       Date:  2016-09-06       Impact factor: 2.388

5.  Granzyme B mediated function of Parvovirus B19-specific CD4(+) T cells.

Authors:  Arun Kumar; Maria F Perdomo; Anu Kantele; Lea Hedman; Klaus Hedman; Rauli Franssila
Journal:  Clin Transl Immunology       Date:  2015-07-03

6.  CD4+ T helper cell responses against human bocavirus viral protein 2 viruslike particles in healthy adults.

Authors:  Juha Lindner; Sandra Zehentmeier; Rauli Franssila; Sascha Barabas; Josef Schroeder; Ludwig Deml; Susanne Modrow
Journal:  J Infect Dis       Date:  2008-12-01       Impact factor: 5.226

Review 7.  Clinical and epidemiological aspects of human bocavirus infection.

Authors:  Juha Lindner; Lüdya Karalar; Sven Schimanski; Heiko Pfister; Wilhelm Struff; Susanne Modrow
Journal:  J Clin Virol       Date:  2008-09-26       Impact factor: 3.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.